Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - stocrin
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpa192389a9068e61de77d4f090e108cd6
identifier: http://ema.europa.eu/identifier
/EU/1/99/111/005
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: STOCRIN 30 mg/mL oral solution
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-a192389a9068e61de77d4f090e108cd6
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/99/111/005
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - stocrin
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Stocrin, which contains the active substance efavirenz, belongs to a class of antiretroviral medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It is an antiretroviral medicine that fights human immunodeficiency virus (HIV) infection by reducing the amount of the virus in blood. It is used by adults, adolescents and children 3 years of age and older. Your doctor has prescribed Stocrin for you because you have HIV infection. Stocrin taken in combination with other antiretroviral medicines reduces the amount of the virus in the blood. This will strengthen your immune system and reduce the risk of developing illnesses linked to HIV infection.
Do not take Stocrin
if you are allergic to efavirenz or any of the other ingredients of this medicine (listed in section 6). Contact your doctor or pharmacist for advice.
if you have severe liver disease.
if you have a heart condition, such as changes in the rhythm or rate of the heart beat, a slow heart beat, or severe heart disease.
if any member of your family (parents, grandparents, brothers or sisters) has died suddenly due to a heart problem or was born with heart problems.
if your doctor has told you that you have high or low levels of electrolytes such as potassium or magnesium in your blood.
if you are currently taking any of the following medicines (see also Other medicines and Stocrin ):
Stocrin must be taken with other medicines that act against the HIV virus. If Stocrin is started because your current treatment has not prevented the virus from multiplying, another medicine you have not taken before must be started at the same time.
This medicine is not a cure for HIV infection and you may continue to develop infections or other illnesses associated with HIV disease.
You must remain under the care of your doctor while taking Stocrin.
Tell your doctor:
Once you start taking Stocrin, look out for:
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor will give you instructions for proper dosing.
The dose for adults is 24 mL once daily.
The dose for Stocrin may need to be increased or decreased if you are also taking certain medicines (see Other medicines and Stocrin).
Stocrin oral solution may be taken with or without food. The dose of Stocrin oral solution in mg is not the same as for Stocrin film-coated tablets.
Stocrin must be taken every day.
Stocrin should never be used alone to treat HIV. Stocrin must always be taken in combination with other anti-HIV medicines. The dose of Stocrin oral solution must be measured using the oral syringe supplied in the carton.
On first use, the bottle adapter must be fitted into the neck of the bottle. To do this, remove the child-resistant cap and the foil seal. The bottle adapter, which is already fixed to the nozzle of the syringe, can then be fitted into the neck of the bottle and pressed firmly down.
Separate the syringe from the adapter. The adapter should now fit closely to the neck so that the cap can be replaced without removing it.
With the bottle upright, fit the tip of the syringe into the bottle adapter.
Turn the bottle upside down with the syringe still in place. Hold the bottle and the syringe firmly in one hand and with the other hand pull back the plunger slightly beyond the mark for the dose required. If air bubbles appear in the syringe, keep the bottle upside down and slowly push in the plunger and pull it back again. Repeat until there are no bubbles in the syringe.
To measure the dose accurately, keep the bottle upside down and push the plunger in slowly until the top of the black ring (the edge nearest the syringe tip) lines up with the dose. Turn the bottle the right way up and remove the syringe. Wipe the adapter and replace the cap tightly over it.
Before giving the dose of the oral solution make sure that the patient is sitting or standing upright. Put the tip of the syringe just inside the mouth, pointing it towards the cheek. Press the plunger slowly to allow time for the medicine to be swallowed. Rapid squirting into the mouth may cause choking. After use, soak the syringe in warm soapy water for at least a minute. Draw the warm soapy water into the syringe until full and then empty completely. Repeat at least three times. Remove the plunger rod from the barrel and thoroughly rinse both parts with warm running water. If parts of the syringe are not clean, repeat the cleaning instructions. Allow the parts to dry completely prior to reassembly. Do not put the syringe in a dishwasher. Use in children and adolescents
The dose for children weighing 40 kg or more is 24 mL once daily.
If you take more Stocrin than you should If you take too much Stocrin contact your doctor or nearest emergency department for advice. Keep the medicine container with you so that you can easily describe what you have taken. If you forget to take Stocrin Try not to miss a dose. If you do miss a dose, take the next dose as soon as possible, but do not take a double dose to make up for a forgotten dose. If you need help in planning the best times to take your medicine, ask your doctor or pharmacist. If you stop taking Stocrin When your Stocrin supply starts to run low, get more from your doctor or pharmacist. This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. The virus may then become harder to treat. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them. When treating HIV infection, it is not always possible to tell whether some of the unwanted effects are caused by Stocrin or by other medicines that you are taking at the same time, or by the HIV disease itself. During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes. The most notable unwanted effects reported with Stocrin in combination with other anti-HIV medicines are skin rash and nervous system symptoms. You should consult your doctor if you have a rash, since some rashes may be serious; however, most cases of rash disappear without any change to your treatment with Stocrin. Rash was more common in children than in adults treated with Stocrin. The nervous system symptoms tend to occur when treatment is first started, but generally decrease in the first few weeks. In one study, nervous system symptoms often occurred during the first 1-3 hours after taking a dose. If you are affected your doctor may suggest that you take Stocrin at bedtime. Some patients have more serious symptoms that may affect mood or the ability to think clearly. Some patients have actually committed suicide. These problems tend to occur more often in those who have a history of mental illness. In addition, some nervous system symptoms (e.g., confusion, slow thoughts and physical movement, and delusions [false beliefs] or hallucinations [seeing or hearing things that others do not see or hear]) may occur months to years after beginning Stocrin therapy. Always notify your doctor immediately if you have these symptoms or any side effects while taking Stocrin. Diarrhoea occurred in children who took Stocrin oral solution and nelfinavir in combination with other antiretroviral medicines. Tell your doctor if you notice any of the following side effects: Very common (affects more than 1 user in 10)
skin rash Common (affects 1 to 10 users in 100)
abnormal dreams, difficulty concentrating, dizziness, headache, difficulty sleeping, drowsiness, problems with coordination or balance
stomach pain, diarrhoea, feeling sick (nausea), vomiting
itching
tiredness
feeling anxious, feeling depressed Tests may show:
increased liver enzymes in the blood
increased triglycerides (fatty acids) in the blood Uncommon (affects 1 to 10 users in 1,000)
nervousness, forgetfulness, confusion, fitting (seizures), abnormal thoughts
blurred vision
a feeling of spinning or tilting (vertigo)
pain in the abdomen (stomach) caused by inflammation of the pancreas
allergic reaction (hypersensitivity) that may cause severe skin reactions (erythema multiforme, Stevens-Johnson syndrome)
yellow skin or eyes, itching, or pain in the abdomen (stomach) caused by inflammation of the liver
breast enlargement in males
angry behaviour, mood being affected, seeing or hearing things that are not really there (hallucinations), mania (mental condition characterised by episodes of overactivity, elation or irritability), paranoia, suicidal thoughts, catatonia (condition in which the patient is rendered motionless and speechless for a period)
whistling, ringing or other persistent noise in the ears
tremor (shaking)
flushing Tests may show:
increased cholesterol in the blood Rare (affects 1 to 10 users in 10,000)
itchy rash caused by a reaction to sunlight
liver failure, in some cases leading to death or liver transplant, has occurred with efavirenz. Most cases occurred in patients who already had liver disease, but there have been a few reports in patients without any existing liver disease.
unexplained feelings of distress not associated with hallucinations, but it may be difficult to think clearly or sensibly
suicide Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the bottle and on the carton after EXP. The expiry date refers to the last day of that month. The bottle of Stocrin oral solution should be used within one month after first opening. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Stocrin contains
Each mL of Stocrin oral solution contains 30 mg of the active substance efavirenz.
The other ingredients are: medium chain triglycerides, benzoic acid (E210) and strawberry/mint flavour [containing benzyl alcohol (E1519) and propylene glycol (E1520)]. What Stocrin looks like and contents of the pack Stocrin 30 mg/mL oral solution is supplied in bottles of 180 mL. An oral syringe with a push-in bottle-neck adapter is included in the carton. Marketing Authorisation Holder Manufacturer Merck Sharp & Dohme B.V. Merck Sharp & Dohme B.V. Waarderweg Waarderweg 2031 BN Haarlem Postbus The Netherlands 2003 PC Haarlem The Netherlands For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgique/Belgi /Belgien MSD Belgium T l/Tel: +32(0)27766dpoc_belux@merck.com Lietuva UAB Merck Sharp & Dohme Tel.: +370 5 278 02 msd_lietuva@merck.com
.: +359 2 819 3info-msdbg@merck.com Luxembourg/Luxemburg MSD Belgium T l/Tel: +32(0)27766dpoc_belux@merck.com esk republika Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 dpoc_czechslovak @merck.com Magyarorsz g MSD Pharma Hungary Kft. Tel.: +361 888 53 hungary_msd@merck.com Danmark MSD Danmark ApS Tlf: +45 44 82 40 dkmail@merck.com Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com Deutschland MSD Sharp & Dohme GmbH Tel: 0800 673 673 673 (+49 (0) 89 4561 0) e-mail@msd.de Nederland Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com Eesti Merck Sharp & Dohme O Tel.: +372 6144 msdeesti@merck.com Norge MSD (Norge) AS Tlf: +47 32 20 73 msdnorge@msd.no E MSD . . . . : + 30-210 98 97 dpoc_greece@merck.com sterreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 dpoc_austria@merck.com Espa a Merck Sharp & Dohme de Espa a, S.A. Tel: +34 91 321 06 msd_info@merck.com Polska MSD Polska Sp. z o.o. Tel.: +48 22 549 51 msdpolska@merck.com France MSD France T l: + 33 (0) 1 80 46 40 Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465inform_pt@merck.com Hrvatska Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 croatia_info@merck.com Rom nia Merck Sharp & Dohme Romania S.R.L. Tel: + 4021 529 29 msdromania@merck.com Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998medinfo_ireland@merck.com Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: + 386 1 5204msd_slovenia@merck.com sland Vistor hf. S mi: +354 535 7Slovensk republika Merck Sharp & Dohme, s. r. o. Tel.: +421 2 58282dpoc_czechslovak@merck.com talia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) medicalinformation.it@msd.com Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0) 9 804info@msd.fi
Merck Sharp & Dohme Cyprus Limited : 80000 673 (+357 22866700) cyprus_info@merck.com Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 (0)77 5700medicinskinfo@merck.com Latvija SIA Merck Sharp & Dohme Latvija Tel: +371 67364 msd_lv@merck.com United Kingdom (Northern Ireland) Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998medinfoNI@msd.com This leaflet was last revised in Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. Package leaflet: Information for the user Stocrin 600 mg film-coated tablets efavirenz Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor, pharmacist or nurse.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Entry 1 - fullUrl = Composition/composition-en-a192389a9068e61de77d4f090e108cd6
Resource Composition:
Generated Narrative: Composition composition-en-a192389a9068e61de77d4f090e108cd6
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/99/111/005status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - stocrin
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpa192389a9068e61de77d4f090e108cd6
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpa192389a9068e61de77d4f090e108cd6
identifier:
http://ema.europa.eu/identifier
/EU/1/99/111/005type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: STOCRIN 30 mg/mL oral solution
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en